Endometriosis: the ongoing quest for therapeutic modulators to prevent cardiovascular adverse outcomes

Benjamin Marchandot, Olivier Morel
European heart journal open · 2025 · vol. 5(3) , pp. oeaf044 · doi:10.1093/ehjopen/oeaf044 · PMID:40370505 · PMC12076400 · W4409582460
Other OA: gold CC0
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This paper reviews therapeutic modulators for endometriosis, focusing on their potential to prevent associated cardiovascular adverse outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-21 · read from full text ⓘ

This review article examines the cardiovascular risks associated with endometriosis and evaluates potential therapeutic strategies to mitigate these adverse outcomes. The authors discuss the pathophysiological links between endometriosis, such as chronic inflammation and hormonal imbalances, and increased cardiovascular disease incidence. They highlight the need for targeted modulators that can address both the gynecological condition and its systemic vascular complications without exacerbating cardiac risk. This paper is centrally about endometriosis — specifically focusing on preventing cardiovascular adverse outcomes in patients with the condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 962 characters · extracted from epmc-fulltextxml · 2 sections · click to expand

Funding

The authors report no external funding support for this work. The work presented here was conducted independently, without financial sponsorship or institutional funding.

Contrib Info

Benjamin Marchandot, Department of Cardiology, University Hospital of Strasbourg, Nouvel Hôpital Civil, 1 place de l’Hôpital, BP 426-67091, Strasbourg 67000, France; Research Unit - UR3074, Translational Cardiovascular Medicine, University of Strasbourg, Strasbourg, France; Groupe pour l’Enseignement et la Recherche Cardiovasculaire en Alsace (GERCA), Strasbourg, France. Olivier Morel, Department of Cardiology, University Hospital of Strasbourg, Nouvel Hôpital Civil, 1 place de l’Hôpital, BP 426-67091, Strasbourg 67000, France; Research Unit - UR3074, Translational Cardiovascular Medicine, University of Strasbourg, Strasbourg, France; Groupe pour l’Enseignement et la Recherche Cardiovasculaire en Alsace (GERCA), Strasbourg, France; Hanoï Medical University, Hanoï, Vietnam.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: epmc-fulltextxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (2)

Source provenance

europepmc
last seen: 2026-10-12T06:17:10.165071+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pmc
last seen: 2026-05-13T20:22:03.195721+00:00
pubmed
last seen: 2026-10-12T06:12:28.011993+00:00
License: CC0 · commercial use OK